Evidence map›Paper›PMID 37724673›Full record

ReviewCurrent medicinal chemistry2024

The Potential Therapeutic Applications of CRISPR/Cas9 in Colorectal Cancer.

Toktam Sahranavard, Shima Mehrabadi, Ghazaleh Pourali, Mina Maftooh, Hamed Akbarzade, Seyed Mahdi Hassanian, Majid Ghayour Mobarhan, Gordon A Ferns, Majid Khazaei, Amir Avan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toktam SahranavardFaculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Shima MehrabadiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh PouraliMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mina MaftoohMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed AkbarzadeMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour MobarhanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsBrighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences
6 · The paper itself

Abstract

The application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/- Cas9 in treating CRC. Further in-depth and systematic research is required to fully realize the potential of CRISPR/Cas9 in CRC treatment and integrate it into clinical practice.

Indexed as

Colorectal NeoplasmsCRISPR-Cas SystemsAnimalsGene EditingGenetic TherapyHumanscancer.colorectal neoplasmsCRISPR-Cas systemsgene editingprecision medicinetherapeutics

Identifiers

PMID37724673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.